Concizumab is a medication being studied for its ability to prevent bleeding episodes in patients with hemophilia A or B who have developed inhibitors. It is used as a prophylactic treatment, meaning it is given regularly to help prevent bleeding rather than treating it after it occurs. The trial aims to see how effective concizumab is compared to not using any regular preventive treatment.

Hemophilia A with inhibitors – Hemophilia A is a genetic disorder where the blood does not clot properly due to a deficiency of clotting factor VIII. In some patients, the body develops inhibitors, which are antibodies that attack the replacement clotting factor, making treatment more challenging. This condition leads to frequent bleeding episodes, which can occur spontaneously or due to injury. Bleeding often happens in joints and muscles, causing pain and swelling. Over time, repeated bleeding into joints can lead to joint damage and reduced mobility. Managing bleeding episodes becomes more complex when inhibitors are present, requiring alternative treatment strategies.

Hemophilia B with inhibitors – Hemophilia B is a genetic disorder characterized by a deficiency of clotting factor IX, leading to improper blood clotting. Similar to Hemophilia A, some individuals develop inhibitors that neutralize the effectiveness of replacement factor IX therapy. This results in increased bleeding episodes, which can be spontaneous or triggered by trauma. Bleeding commonly affects joints and muscles, leading to pain and potential joint damage over time. The presence of inhibitors complicates the management of the disease, necessitating different therapeutic approaches to control bleeding. Regular monitoring and specialized care are essential to manage the condition effectively.